This study is designed to assess the systemic exposure and pharmacokinetics of sunscreen active ingredients (avobenzone, oxybenzone, ecamsule, octocrylene homosalate, octisalate and octinoxate) when sunscreen product is applied under maximal use conditions.
Part 1 is an open-label, randomized, 4-arm study in 24 healthy adult subjects with the primary objective to explore whether the active components (avobenzone, oxybenzone, ecamsule and octocrylene) of 4 sunscreen products (1 sunscreen product in each arm) are absorbed into the systemic circulation when a sunscreen product is applied under maximal use conditions.
One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2. In addition, 3 new sunscreen products are included in Part 2.
Part 2 is an open label, 4-arm study in 48 healthy adult subjects with the primary objective to assess the pharmacokinetics of the active components in the selected product from Part 1 and 3 additional products with a combination of active ingredients (avobenzone, oxybenzone, octocrylene, ecamsule homosalate, octisalate and octinoxate as applicable/contained in the different products).

Start Date18 Jul 2018

Sponsor / Collaborator

US Food & Drug Administration

[+1]

NCT02668536 / CompletedPhase 1IIT

Assessing the Safety and Efficacy of Multifunctional Skin-adhesive Nanoparticles for UV Protection in Humans

The initial focus of the study will be on safety, sun protection factor (SPF) characterization, and substantivity (duration of protection) studies. The primary outcome of the study will be to measure the sun protection factor (SPF) of a bioadhesive nanoparticles (BNP) formulation in 20-25 healthy volunteers with fair skin.

Start Date17 Jul 2017

Sponsor / Collaborator

Yale University

NCT00530387 / CompletedNot Applicable

A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe.

It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).
The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis.
Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing.
The study will run for one year, during which time it is planned to recruit 1,000 patients.

Start Date01 Jul 2008

Sponsor / Collaborator

NHS Tayside

100 Clinical Results associated with Oxybenzone

100 Translational Medicine associated with Oxybenzone

100 Patents (Medical) associated with Oxybenzone

1,570

Literatures (Medical) associated with Oxybenzone

01 Feb 2025·Journal of Environmental Sciences

Exposure of individuals aged 18–44 years to personal care products in Beijing, China: Exposure profiles, possible influencing factors, and risk assessment

Article

Author: Zhu, Ying ; Hu, Xiaojian ; Wang, Xiaochen ; Zhang, Xu ; Lin, Xiao ; Sun, Qi ; Han, Linxue

Personal care products (PCPs) are a class of emerging pollutants that have attracted public concern owing to their harmful effects on humans and the environment. Biomonitoring data is valuable for insight the levels of PCPs in the human body and can be crucial for identifying potential health hazards. To gain a better understanding of timely exposure profiles and health risk of reproductive-age population to PCPs, we determined six parabens, six benzophenone-type ultraviolet filters, and three disinfectants in 256 urine samples collected from young adults aged 18-44 years in Beijing, China. The urinary levels of benzophenone-3 (BP-3) and 4-hydroxybenzophenone (4-OHBP) were significantly higher in summer compared to winter, suggesting these compounds have different seasonal usage patterns. Moreover, the total concentration of 15 PCPs in female was 430 ng/mL, approximately two times higher than that in male. P‑chloro-m-xylenol (PCMX), as a new type of antibacterial agent, has the greatest level among all target analytes, indicating the increasingly use of this antibacterial alternative recently. Five potential influencing factors that lead to the elevated exposure level of PCPs were identified. Over 19% of the target population had a high hazard index value (greater than 1) which was attributed to exposure to propyl paraben (PrP), benzophenone-1 (BP-1), BP-3 and PCMX, indicating that PCPs may pose a relatively high exposure risk at environmental levels that should be a cause for concern.

01 Dec 2024·Toxicology

Prenatal exposure to low doses of benzophenone-3 elicits disruption of cortical vasculature in fetuses through perturbations in Wnt/β-catenin signaling correlating with depression-like behavior in offspring mice

Article

Author: Zhu, Dan ; Hu, Haichen ; Luo, Yijun ; Wang, Qi ; Zou, Lianhong ; Yang, Ying ; Zhong, Xiali ; Zeng, Xiangyu ; Feng, Yang ; Zhang, Yangjian ; Guo, Lan

Benzophenone-3 (BP-3), commonly used in personal care products, is routinely detected in environmental and human matrices. Evidence delineates a correlation between gestational BP-3 exposure and emotional and social disorders in children and adolescents. However, sensitive target cells and the mode of action underlying the early responses to environmentally relevant level of BP-3 exposure remain unclear. In this study, 0.3 and 3 mg/kg of BP-3 were administered to pregnant mice. Compared with the control group, the cortical blood vessel development process manifested the highest susceptibility to BP-3 exposure using transcriptomic sequencing at embryonic day 14 (E14). Notably, the diminution in vascular density and tight junction proteins presence was observed in the fetal cortex at E14, concomitant with the suppressed transcriptional activity of genes essential to angiogenesis and barrier formation. Strikingly, the investigation revealed that BP-3 exposure impeded vascular sprouting in aortic ring explants and neuroendothelial migration, implicating the Wnt/β-catenin signaling pathway. Moreover, BP-3 exposure compromised perivascular neural stem cell differentiation. Cortical vascular injury correlated with the exhibition of depression-like behavior in four-week postnatal progeny. These insights underscore the cerebrovasculature as an early sensitive target for low doses of BP-3 exposure, fostering the development of biomarkers and the establishment of the adverse outcome pathway framework for BP-3 hazard evaluation.

01 Dec 2024·Environmental Research

Associations of prenatal maternal urinary concentrations of triclosan and benzophenone-3 with cognition in 7.5-month-old infants

Article

Author: Woodbury, Megan L ; Sprowles, Jenna ; Musaad, Salma ; Woodbury, Megan L. ; Cragoe, Nicholas ; Schantz, Susan L. ; Schantz, Susan L ; Enright, Elizabeth ; Aguiar, Andréa

BACKGROUNDEndocrine-disrupting chemicals (EDCs) have been linked to adverse health outcomes and prenatal exposure is known to impact infant and child development. However, few studies have assessed early developmental consequences of prenatal exposure to two common phenolic compounds, benzophenone-3 (BP-3) and triclosan (TCS).OBJECTIVEWe evaluated the relationship of prenatal exposure to BP-3 and TCS with infant cognition at 7.5 months via performance on a visual recognition memory (VRM) task.METHODSDrawing from the Illinois Kids Development Study (IKIDS) cohort, prenatal exposure to BP-3 and TCS was assessed in pools of five urine samples collected from each woman across pregnancy. Cognition was measured in 310 infants using a VRM task assessing information processing speed, attention, and recognition memory through infrared eye-tracking. Generalized linear regression estimated exposure-outcome associations, followed by stratification to investigate modification of associations by infant sex and stimulus set.RESULTSSampled mothers were more likely to be white, college educated, and middle or high income relative to the US population. Mean chemical exposures were significantly higher than those of adult women in the NHANES cohort. In models adjusted for income, gestational age at birth, and testing age, prenatal BP-3 exposure was associated with an increase in run duration (average time spent looking at the stimuli before looking away) (β = 0.0011, CI -0.0001:0.0022), indicating slower information processing speed, while TCS was associated with significantly longer time to familiarization (time to accrue a total of 20 s of looking time to the stimuli) (β = 0.0686, CI 0.0203:0.1168, p < 0.01), indicating poorer attention. Stratum-specific analyses isolated both effects to male infants who viewed the second of two stimulus sets.CONCLUSIONHigher prenatal exposure to triclosan was associated with poorer attention in infancy, while benzophenone-3 may be associated with slower information processing speed, particularly among males.

News (Medical) associated with Oxybenzone

07 Nov 2023

·www.prnewswire.com

ELEMENT EIGHT Closes $6M in SAFE Funding, launches a $6.25M Series A Round, Appoints Jake Galtere and Kristi McCluer as CMO and VP Global Sales and Education to Fuel Continued Expansion

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- ELEMENT EIGHT, a premium brand bringing the cutting-edge advances of biomedicine to skincare through its proprietary OATH™: Oxygen Amplified Therapy, today announced that it has closed $6M in funding in a SAFE round. The brand reported $2.5M of investment from its existing investors, and was able to attract an additional $3.5M from new investors. Continue Reading "With forty five percent of the round coming from surgeons, dermatologists, and PhD scientists, we have a strong validation of the scientific acumen of the brand. We were very pleased to also have participation from private family offices with experience in beauty investing, who accounted for thirty four percent of the round," said Company Chairman Bradley Patt. "Finally, realizing fourteen percent participation from management, employees and members of the company's board of directors shows excitement about the Company's progress from the people inside." Including the successful SAFE Round that just closed, the Company has raised a total of $7.9M to date. Immediately upon closing this SAFE funding, the Company has announced it will proceed on to a new $6.25M Series A Round to continue to accelerate the growth of potent skincare products. ELEMENT EIGHT is redefining the anti-aging skincare market by bringing cutting-edge advances from the world of biotechnology to skincare. With its proprietary OATH™: Oxygen Amplified Therapy technology, which mimics the function of hemoglobin to deliver 20x more oxygen directly to skin cells up to 700 microns deep, ELEMENT EIGHT addresses skin's biological performance and counteracts the key signs of aging. This technology was developed by a team of world-renowned spine surgeons, biomaterial engineers, dermatologists and clinical researchers over the course of a decade, and has attracted investors and consumers on the forefront of the high-performance skincare industry to the brand. Founder and Board Member Gerard Camme said "ELEMENT EIGHT has a unique point of difference thanks to the innovative technology of OATH™, and fits into the fastest growing segment of the global skincare market. As we look ahead, we're excited to continue to innovate on the groundbreaking advances of our multi-expert team to bring new products to market and make ELEMENT EIGHT accessible on a wider scale." In addition to this newest round of funding, ELEMENT EIGHT announced the appointment of Jake Galtere as Chief Marketing Officer and Kristi McCluer as Vice President of Global Sales and Education to drive the brand's global strategy and oversee continued expansion. With over a decade of experience developing digital marketing strategies across the luxury market, Jake Galtere joins ELEMENT EIGHT after most recently serving as Vice President of Marketing for Ralph Lauren and Azzaro Fragrances. He has held posts at leading brands including Lancôme, YSL Beaute and Mugler, working to accelerate growth, driving innovation, awareness and consumer engagement. "Joining Element Eight was an easy decision. The brand has an extremely distinct DNA, from its origin in spine surgery to the multi-expert team who continue to innovate for the consumer," said Jake. " Importantly, the products really do work. I'm extremely excited to help bring this brand to market." Appointed as Vice President of Global Sales and Education, Kristi McCluer joins the ELEMENT EIGHT team with over 15 years of experience in luxury sales. Coming from the L'Oréal Luxury Division, Kristi was responsible for omni-channel retailer business development and strategy. Most recently, she earned an Executive Certificate in Digital Marketing Analytics from MIT. "I am thrilled to join ELEMENT EIGHT to advance the skincare industry. Our technology is unique and is proven through robust scientific research and clinical studies," said Kristi. "I see a remarkable opportunity to empower customers and redefine the way we experience healthy skin." "Jake and Kristi bring a wealth of expertise in the luxury beauty industry, having played central roles at leading luxury brands. They bring with them extensive experience and a deep understanding of the beauty industry that will be pivotal to the development of our global strategy and expansion of the ELEMENT EIGHT brand," said Gerard Camme. "I am incredibly pleased to appoint Jake and Kristi and look forward to supporting their vision for the brand in this next phase of our growth." As the Company rolls out its Series A offering it is pleased to announce it has joined Ohana & Co.'s incubation platform: "We have been following Element Eight since its inception and have been impressed with the traction gained and what CEO Gerard Camme has achieved in just one year since the launch," said Ohana & Co. Managing Partner, Karine Ohana. The Company is also excited to announce that Martin Brok, accomplished global executive with over 35 years of experience in senior roles, including as Global CEO of Sephora, Nike, Starbucks, and The Coca-Cola Co, will join the company's Business Advisory Board and will participate in the Series A financing. "I see dozens of ideas in this space," said Mr. Brok, "Element Eight stood out to me as a very different premium offering that is entering the most dynamic segment of the skincare market: heavy science and luxury leaning with a distinct voice that separates itself from the clutter and fills a white space. I am excited to be a part of this team." About ELEMENT EIGHT Founded in 2022, ELEMENT EIGHT is bringing the latest advances in oxygen-infusing medicine to skincare. Developed by a world-renowned team of spine surgeons, biomaterial engineers, dermatologists, clinical researchers and systems group engineers. Collectively they hold 16 MD-PHDs, 120 medical patents and over 100,000 uses of technologies they have developed. The team spent over a decade developing the brand's proprietary OATH™: Oxygen Amplified Therapy technology mimics the function of hemoglobin to deliver 20x more oxygen directly to skin cells up to 700 microns deep, counteracting the key signs of aging, all of which are caused by oxygen depletion in the skin. True to the brand's ethos of clean science, all ELEMENT EIGHT products are formulated without parabens, GMO's PEG's, sulfates, phthalates, formaldehyde or formaldehyde releasers, oxybenzone and octinoxate, hydroquinone, triclosan, coal tar, methylisothiazolinone and methylchloroisothiazolinone, and insoluble plastic microbeads. ELEMENT EIGHT is 100% vegan, gluten-free, cruelty-free and fragrance-free. ELEMENT EIGHT's packaging was developed with environmental impact at top of mind and is recyclable and FSC certified. For more information, visit the brand at . Media Contact: Paige Davis, [email protected], +1 502 472 8611 SOURCE ELEMENT EIGHT

Executive Change

09 May 2023

·www.drugs.com

Summer's Near: What's the Best Sunscreen for You?

WEDNESDAY, May 10, 2023 -- It’s easy to keep your skin safer in the summer sun if you have the right sunscreen. UCLA Health offers some tips for picking the best type and SPF level. Getting sunburned just five times in a lifetime doubles the risk of getting melanoma, the most serious skin cancer, so making sure you’re protected is worth the effort, the experts at UCLA Health said in a news release. Types of sunscreens can be divided into two categories: mineral and chemical. Each type has its pros and cons. Mineral sunscreen sits on the skin’s surface. It physically blocks ultraviolet (UV) light before those rays can penetrate the skin. While offering instant protection, it can be harder to rub in, needs to be applied more frequently and tends to leave a white film on the skin. Yet, it’s also gentler than chemical sunblock, making it a good choice for sensitive skin, according to UCLA Health. Mineral sunscreen contains titanium dioxide and zinc oxide, both recognized as safe and effective by the U.S. Food and Drug Administration. Chemical sunscreens allow UV light to penetrate skin, after which the chemicals convert the UV light into heat. This is released from the skin. The downsides are that chemical sunscreens need to be applied at least 20 minutes before sun exposure and there are concerns about the ingredients in chemical sunscreens, especially oxybenzone, according to UCLA Health. Some of the ingredients in these sunscreens may cause environmental issues, including damage to coral reefs. They may also pose health risks such as hormone disruption and allergic skin reactions. Yet, they’re also easy to rub in and leave less residue. The FDA is waiting for more safety data before labeling them as safe and effective. Experts say the health risks of sun exposure far outweigh the potential risk of absorbing sunscreen chemicals. When choosing the SPF, or sun protection factor, know that the higher the number, the longer the protection should last. With SPF 30, for example, it should take you 30 times longer to burn than if you weren’t wearing sunscreen. But there’s more to it than that. All sunscreens protect against UVB rays, the main cause of sunburn and skin cancers. Broad-spectrum SPF also protects against UVA rays. Sunscreen that is SPF 30 lets 3% of rays through. A higher protection number, SPF 50, allows 2% of rays through. It's important to reapply, especially if you’re sweating and swimming. The Skin Cancer Foundation recommends using water-resistant, broad-spectrum sunscreen with SPF 30 or higher. You should reapply every two hours or immediately after swimming or sweating. SPF protection above 50 is only slightly better than SPF 30, so reaching for a higher number doesn’t matter as much. What’s important about the application method is this: what you are more likely to use and reapply. If that’s lotion, the Skin Cancer Foundation recommends applying at least 1 ounce, which is also 2 tablespoons or the amount that fills a shot glass. For spray, keep applying until your skin glistens. The bottle may say “no rub,” but smoothing it into your skin will ensure even coverage. Avoid using aerosol sprays on or near your face because they can contain ingredients that, when inhaled deeply, may cause irritation and possibly damage your lungs. It may be better to avoid spray for young children, but you can also spray it onto hands and rub it onto your face or your child. Stick sunscreen is great for small areas, such as the face and ears. Make four passes with the sunscreen over each area you’re protecting, UCLA Health advises. Rub the sunscreen in afterward, for even coverage. Even with this protection, opt to seek shade and wear protective clothing whenever possible. Sources UCLA Health, news release Posted May 2023

02 Dec 2022

·www.sciencedaily.com

Microplastics could make other pollutants more harmful

Microplastics -- small plastic pieces less than five millimeters in length -- are becoming a ubiquitous ecological contaminant. Studies suggest that on their own, these tiny bits are potentially harmful, and it's unclear what effect they could have on pollutants that latch onto them. Now, researchers show that, when attached to microplastics, UV filters used in products such as sunscreens can make chromium metal more toxic. Microplastics -- small plastic pieces less than five millimeters in length -- are becoming a ubiquitous ecological contaminant. Studies suggest that on their own, these tiny bits are potentially harmful, and it's unclear what effect they could have on pollutants that latch onto them. Now, researchers reporting in ACS' Environmental Science & Technology Letters show that, when attached to microplastics, UV filters used in products such as sunscreens can make chromium metal more toxic. Because microplastics can accumulate other environmental contaminants on their surfaces, such as heavy metals or organic molecules, they could pose even more of a problem for wildlife, plants or humans than originally thought. Previous research has shown that heavy metals can easily attach to microplastics, and that this combination could potentially harm aquatic life. But beyond just sticking to other contaminants, microplastics and the cocktail of substances on them could interact with each other, altering their chemical properties. For example, certain metals, such as chromium (Cr), might take on different oxidation states while on the surfaces of microplastics. And although Cr(III) is relatively safe, Cr(VI) is toxic. So, Kelvin Sze-Yin Leung and colleagues wanted to investigate, for the first time, how the oxidation state of Cr could change when bound to microplastics, and how this could be affected by a common organic contaminant: UV filter molecules. The researchers created mixtures of Cr and polystyrene microplastic particles both with and without benzophenone-type UV filters. The team found that microplastics could aggregate even more Cr in the presence of a UV filter. In addition, the oxidation state of Cr was higher in the mixtures containing the filters. Finally, the team tested whether this increased oxidation state translated to environmental toxicity for a population of microalgae. The microalgae's growth was inhibited when exposed to the mixture containing the filter molecule, suggesting that Cr was now in its more toxic form. According to the researchers, this means that microplastics can aid in transforming pollutants into a more harmful form -- a previously unproven interaction. The authors acknowledge funding from the Hong Kong Research Grants Council and the Hong Kong Baptist University Seed Fund.

100 Deals associated with Oxybenzone

External Link

KEGG	Wiki	ATC	Drug Bank
D05309	Oxybenzone	D02B	DB01428

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sunburn	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03582215 (CTgov)	Phase 1	-	72	Part 1: Cream (Part 1: Cream)	titmtjzyac(zrirwicemv) = ggrsimmgtn boyrcrtizw (gaidawlake, omxozybast - odudtleecc) View more	-	21 Apr 2020
				Octocrylene+Avobenzone+Oxybenzone (Part 1: Lotion)	titmtjzyac(zrirwicemv) = omlvbypjxl boyrcrtizw (gaidawlake, nmogkelnit - rfvftbzqhp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis